- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01411709
A Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress
A Pilot Study On The Effect Of Vitano® On Physiological And Psychological Responses To Psychological Stress Assessed Under Laboratory Conditions And In Everyday Life
A pilot investigation into the stress relieving properties of Vitano® which will assess the following hypotheses
Individuals exposed to Vitano® will demonstrate diminished blood pressure and heart rate responses to mental stress compared to individuals in the control condition
Physiological recovery (BP, HR and cortisol) from mental stress will be enhanced in individuals exposed to Vitano® compared to individuals in the control condition
Vitano® will have positive effects on cognitive functioning.
Subjective ratings of stress will be reduced in individuals exposed to Vitano® compared to individuals in the control condition
There will be a significant improvement in subjective well-being in individuals taking Vitano®.
Studieoversigt
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 4
Kontakter og lokationer
Studiesteder
-
-
Surrey
-
Guildford, Surrey, Det Forenede Kongerige, GU2 7XP
- University of Surrey
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- subject is able to read and understand the Informed Consent Form (ICF), and understand study procedures.
- The subject has signed the ICF.
- Healthy male or female subjects aged 18-35 years inclusive. Attempts will be made to achieve an equal gender ratio through appropriate screening procedures, but a failure to do so will not preclude analysis of the final data set.
- A score above 30 on the Spielberger State-Trait Anxiety Inventory (STAI).
- The subject agrees to use suitable methods of contraception during the study and for 3 months afterwards.
- The subject is a non-smoker.
- The subject is, in the opinion of the Investigator, healthy on the basis of medical history, vital signs, and the results of routine laboratory tests.
Exclusion Criteria:
- The subject is pregnant or breast feeding.
- The subject consumes more than 5 caffeine-containing beverages per day.
- The subject is colour blind.
- Clinically significant hepatic or renal abnormality as determined by laboratory tests.
- BMI above 33.
- History of alcohol, narcotic, benzodiazepine, or other substance abuse or dependence within the 12 months preceding Visit 1.
- Positive alcohol breath test at any visit. A repeat test will not be allowed. [NOTE: subjects must be told to avoid consumption of alcoholic beverages for at least 24 hours prior to attending the Centre].
- Use of any other medication which may interfere with study outcome and/or interfere with IMP within the 2 weeks or 5 half lives preceding the first treatment phase, with the exception of contraceptive pill, non-steroidal analgesics, and paracetamol. [NOTE: Concomitant medications which do not influence study outcome and/or do not interfere with IMP may be allowed at the discretion of the Investigator].
- Current participation in another clinical trial with an investigational or non-investigational drug or device, or participation in another clinical trial within the 3 months preceding Visit 1 (screening visit).
- Any condition that, in the Investigator's opinion, compromises the subject's ability to meet protocol requirements or to complete the study.
- Moderate or severe anxiety* *If participants are found to have moderate or severe anxiety during the screening process then they will be referred to the University Counselling service.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Vitano
|
two 200mg tablets per day for 14 days
|
|
Ingen indgriben: Control
No tablets - control group
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Blood pressure measurements
Tidsramme: Measurements over 14 days (Day 0, Day 7 and Day 14)
|
Blood pressure readings taken under laboratory conditions during cognitive testing and relaxation periods
|
Measurements over 14 days (Day 0, Day 7 and Day 14)
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Measures of cognitive function
Tidsramme: 14 days
|
cognitive function assessed four times during the 14 day study period
|
14 days
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- CRC287
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Mild Stress/Anxiety
-
NYU Langone HealthRekruttering
-
Ludwig-Maximilians - University of MunichBayerisches Staatsministerium für Gesundheit, Pflege und PräventionRekrutteringMild kognitiv svækkelse | Mild demensTyskland
-
Fondazione IRCCS Policlinico San Matteo di PaviaAfsluttetMild akut galdevejspankreatitisItalien
-
Dr. Grace ParragaCyclomedica Australia PTY LimitedIkke rekrutterer endnu
-
Hackensack Meridian HealthAktiv, ikke rekrutterende
-
University of WashingtonNational Institute on Aging (NIA)RekrutteringMild kognitiv svækkelse (MCI) | Demens, mildForenede Stater
-
Indivi AGRekrutteringMild kognitiv svækkelse (MCI) | Mild Alzheimers sygdomForenede Stater
-
Saglik Bilimleri UniversitesiAnkara UniversityRekrutteringAmnestisk mild kognitiv svækkelse | Amnestisk mild kognitiv lidelseKalkun
-
Laikο General Hospital, AthensRekrutteringMild autonom kortisolsekretion (MACS)Grækenland
-
Amenity Health, Inc.RekrutteringMild obstruktiv søvnapnøForenede Stater